The recent US approval of a new low dose of colchicine 0.5 mg (Lodoco; Agepha Pharma) with a broad indication for use in atherosclerotic cardiovascular disease (ASCVD) represents a completely new ...

Colchicine use was linked to a 12% reduction in the risk for total joint arthroplasty among patients with gout. Colchicine use is associated with a modest reduction in the long-term risk for total ...

Please provide your email address to receive an email when new articles are posted on . WASHINGTON — The use of colchicine for gout flare prevention imparts a “modest” decrease in the risk for knee or ...

A large price increase for colchicine in 2010 led to a significant falloff in its use for gout that persisted for the next decade while emergency and rheumatology visits for gout rose, suggesting ...

BASEL, Switzerland—Low-dose colchicine doesn’t significantly reduce MACE in patients who have had a nonsevere ischemic stroke or high-risk TIA, according to the results of the CONVINCE trial. Through ...

The largest trial to examine the impact of colchicine in acute myocardial infarction (MI) found that both acute and long-term colchicine use did not reduce cardiovascular death, myocardial infarction, ...

The patient arrived in my clinic, their right big toe the color of a spring strawberry. The lightest touch caused exquisite pain. Fortunately, I was able to prescribe a pill (an ancient medicine, ...

The media reports that colchicine, a very old drug, has now been discovered to reduce the risk of recurrent heart disease and has a new FDA indication. Of course, the “discovery” has taken 10 years, ...

Gout is the most common form of inflammatory arthritis, with a worldwide prevalence of approximately 4%. The accumulation of monosodium urate crystals in gout leads to the clinical manifestations of ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Three trials presented at the European Society of ...

Due to a policy decision in 2010 by the U.S. Food and Drug Administration (FDA), the price of a prescription for the therapeutic gout drug colchicine increased nearly 16-fold from $11.25 in 2009 to ...